Abstract
Allogeneic stem cell transplantation (allo-SCT) is a curative therapy for different life-threatening malignant and non-malignant hematologic disorders. Acute graft-vs.-host disease (aGVHD) and particularly gastrointestinal aGVHD remains a major source of morbidity and mortality following allo-SCT, which limits the use of this treatment in a broader spectrum of patients. Better understanding of aGVHD pathophysiology is indispensable to identify new therapeutic targets for aGVHD prevention and therapy. Growing amount of data suggest a role for T helper (Th)17 cells in aGVHD pathophysiology. In this review, we will discuss the current knowledge in this area in animal models and in humans. We will then describe new potential treatments for aGVHD along the Th17 axis.
Publication types
-
Research Support, Non-U.S. Gov't
-
Review
MeSH terms
-
Acute Disease
-
Animals
-
Antibodies, Monoclonal, Humanized / therapeutic use*
-
Clinical Trials as Topic
-
Cytokines / antagonists & inhibitors
-
Cytokines / biosynthesis
-
Cytokines / immunology
-
Disease Models, Animal
-
Gastrointestinal Tract / drug effects*
-
Gastrointestinal Tract / immunology
-
Gastrointestinal Tract / pathology
-
Graft vs Host Disease / immunology
-
Graft vs Host Disease / pathology
-
Graft vs Host Disease / prevention & control*
-
Hematologic Diseases / immunology
-
Hematologic Diseases / pathology
-
Hematologic Diseases / therapy*
-
Hematopoietic Stem Cell Transplantation*
-
Humans
-
Liver / drug effects
-
Liver / immunology
-
Liver / pathology
-
Mice
-
Molecular Targeted Therapy
-
Skin / drug effects
-
Skin / immunology
-
Skin / pathology
-
Th17 Cells / drug effects*
-
Th17 Cells / immunology
-
Th17 Cells / pathology
-
Transplantation, Homologous
Substances
-
Antibodies, Monoclonal, Humanized
-
Cytokines